Swedbank AB Has $302.82 Million Holdings in Boston Scientific Corporation $BSX

Key Points

• Swedbank AB increased its holdings in Boston Scientific Corporation by 114.5% during the second quarter, now owning 2,819,249 shares valued at approximately $302.82 million.
• Boston Scientific reported a revenue of $5.06 billion for the latest quarter, exceeding analysts' expectations and achieving a 22.8% increase compared to the previous year.
• Equities research analysts have given Boston Scientific a consensus rating of "Buy", with an average price target of $118.04, while several firms have recently raised their price objectives for the stock.

Swedbank AB raised its holdings in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 114.5% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,819,249 shares of the medical equipment provider's stock after purchasing an additional 1,505,019 shares during the quarter. Swedbank AB owned approximately 0.19% of Boston Scientific worth $302,816,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of BSX. Brighton Jones LLC boosted its holdings in shares of Boston Scientific by 0.8% during the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider's stock worth $2,445,000 after buying an additional 226 shares during the period. Bank Pictet & Cie Europe AG lifted its position in Boston Scientific by 40.8% during the fourth quarter. Bank Pictet & Cie Europe AG now owns 73,096 shares of the medical equipment provider's stock worth $6,529,000 after acquiring an additional 21,173 shares during the last quarter. Highview Capital Management LLC DE boosted its holdings in shares of Boston Scientific by 6.2% during the fourth quarter. Highview Capital Management LLC DE now owns 24,507 shares of the medical equipment provider's stock worth $2,189,000 after acquiring an additional 1,439 shares during the period. State of Wyoming boosted its holdings in shares of Boston Scientific by 119.5% during the fourth quarter. State of Wyoming now owns 2,660 shares of the medical equipment provider's stock worth $238,000 after acquiring an additional 1,448 shares during the period. Finally, Waverly Advisors LLC boosted its holdings in shares of Boston Scientific by 24.2% during the fourth quarter. Waverly Advisors LLC now owns 11,174 shares of the medical equipment provider's stock worth $998,000 after acquiring an additional 2,179 shares during the period. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Boston Scientific

In other Boston Scientific news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the company's stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $105.43, for a total value of $5,271,500.00. Following the completion of the transaction, the executive vice president owned 178,342 shares of the company's stock, valued at $18,802,597.06. This represents a 21.90% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Edward J. Ludwig sold 4,000 shares of the company's stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $106.03, for a total value of $424,120.00. Following the completion of the transaction, the director directly owned 18,479 shares of the company's stock, valued at approximately $1,959,328.37. The trade was a 17.79% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 174,214 shares of company stock worth $18,397,457. 0.50% of the stock is currently owned by insiders.

Boston Scientific Price Performance

Shares of NYSE BSX traded down $0.92 during trading hours on Monday, hitting $96.91. 11,012,552 shares of the stock were exchanged, compared to its average volume of 8,405,870. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37. The company has a market cap of $143.60 billion, a PE ratio of 57.69, a price-to-earnings-growth ratio of 2.36 and a beta of 0.65. The company's fifty day simple moving average is $104.25 and its two-hundred day simple moving average is $102.08. Boston Scientific Corporation has a 1-year low of $80.64 and a 1-year high of $109.50.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, beating the consensus estimate of $0.72 by $0.03. The business had revenue of $5.06 billion during the quarter, compared to the consensus estimate of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The firm's revenue was up 22.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, sell-side analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on BSX shares. Needham & Company LLC restated a "buy" rating and set a $121.00 price objective on shares of Boston Scientific in a report on Friday. Barclays boosted their price objective on Boston Scientific from $125.00 to $133.00 and gave the stock an "overweight" rating in a report on Thursday, July 24th. Jefferies Financial Group restated a "hold" rating on shares of Boston Scientific in a report on Monday, July 21st. Royal Bank Of Canada restated an "outperform" rating on shares of Boston Scientific in a report on Thursday, July 24th. Finally, Wells Fargo & Company lifted their price target on shares of Boston Scientific from $118.00 to $124.00 and gave the company an "overweight" rating in a research report on Thursday, July 24th. Three investment analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and one has issued a Hold rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus price target of $118.04.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.